| Literature DB >> 30515096 |
Gonzalo Artiach1, Miguel Carracedo1, Joan Clària2, Andres Laguna-Fernandez1, Magnus Bäck1,3.
Abstract
Intimal hyperplasia remains a significant clinical problem in for example coronary artery bypass graft failure. Since omega-3 fatty acids reduce intimal hyperplasia, we hypothesized that the G protein-coupled receptor ChemR23 for the omega-3-derived pro-resolving lipid mediator resolvin E1 drives those effects. ChemR23+/+ and ChemR23-/- mice were generated with or without introduction of the Caenorhabditis elegans fat-1 transgene, which leads to an endogenous omega-3 fatty acid synthesis and thus increasing the substrate for resolvin E1 formation. ChemR23 deletion significantly increased intimal hyperplasia 28 days after ligation of the left common carotid artery. Mice expressing the fat-1 transgene showed reduced intimal hyperplasia independently of ChemR23 expression. ChemR23-/- Vascular smooth muscle cells (VSMCs) exhibited a significantly lower proliferation compared with VSMCs derived from ChemR23+/+ mice. In contrast, ChemR23-/- peritoneal macrophages had significantly higher mRNA levels of pro-inflammatory cytokines compared with ChemR23+/+ macrophages. Finally, conditioned media (CM) transfer from ChemR23-/- macrophages to VSMCs significantly increased VSMC proliferation compared with CM from ChemR23+/+ macrophages. Taken together, these results point to a dual effect of ChemR23 in resolution pharmacology by directly stimulating VSMC proliferation and at the same time suppressing macrophage-induced VSMC proliferation. In conclusion, these differential effects of ChemR23 signaling in VSMC and macrophages open up a novel notion for intimal hyperplasia pathophysiology, where ChemR23-transduced effects on the vascular wall may vary, and even be opposing, depending on the degrees of resolution of inflammation.Entities:
Keywords: intimal hyperplasia; macrophage; omega-3; resolution of inflammation; smooth muscle cells
Year: 2018 PMID: 30515096 PMCID: PMC6255922 DOI: 10.3389/fphar.2018.01327
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
FIGURE 1ChemR23 deletion promotes intimal hyperplasia under pro-inflammatory conditions. (A) Schematic representation of in vivo experimental procedure. (B) Mouse intima hyperplasia quantification in: ChemR23+/+ n = 7, ChemR23-/- n = 7, fat-1tg ChemR23+/+ n = 6, fat-1tg ChemR23-/- n = 8; after left common carotid ligation, and representative H&E stained photomicrographs. (C) Ly6G+ (neutrophil) ChemR23+/+ n = 5, ChemR23-/- n = 7 and Mac-2 (macrophage) ChemR23+/+ n = 4, ChemR23-/- n = 7 immunohistochemistry quantification, and representative photomicrographs. Data represent mean ± SEM. P-values derive from (B) 2-way ANOVA, (C) Student’s t-test.
FIGURE 2ChemR23 deletion alters the Vascular smooth muscle cells (VSMC) and macrophage phenotype. (A) Basal ChemR23+/+ and ChemR23-/- VSMC proliferation (48h) in vitro, assessed by WST-1. (B) mRNA expression of LPS-activated (100 ng/mL, 24 h) peritoneal macrophages in vitro. (C) VSMC proliferation (48 h) treated with conditioned media (CM) derived from LPS-activated ChemR23+/+ and ChemR23-/- macrophages. For VSMC n = 3/group, for macrophages n = 4/group. Data represent mean ± SEM. P-values derive from Student’s t-test.